Physician profile
Benito Calderon
NPI 1396799904
$12,265.42
in general payments reported to CMS, 2019-2025
54 companies · $1,934 in 2025
The $1,934 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,793 · 2020: $2,098 · 2021: $1,166 · 2022: $963 · 2023: $1,081 · 2024: $2,231 · 2025: $1,934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,246.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,522.82 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,248.66 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $1,198.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,015.70 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $569.54 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $559.64 | 2019-2025 | Jardiance |
| Abbott Laboratories | $510.57 | 2021-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $498.38 | 2024-2025 | Gemtesa |
| Abbvie INC. | $445.80 | 2019-2025 | Qulipta |
| Amgen INC. | $425.34 | 2019-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $420.02 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $393.15 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $368.75 | 2022-2025 | |
| Lilly USA, LLC | $293.49 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $263.10 | 2019-2024 | Xarelto |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benito Calderon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.